John W. Marks
University of Texas MD Anderson Cancer Center
27 Papers
599 Citations
John W. Marks is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Gelonin & Immunotoxin. The author has an hindex of 18, co-authored 27 publications. Previous affiliations of John W. Marks include University of Texas at Austin & Rice University.
Chat about Author
Papers
Aptamer:toxin conjugates that specifically target prostate tumor cells
Ted C. Chu,John W. Marks,Laura A. Lavery,Sarah Faulkner,Michael G. Rosenblum,Andrew D. Ellington,Matthew Levy +6 more
TL;DR: The results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets and promote uptake into target cells but also decreases the toxicity of gelonin in non-target cells.
321
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Liesbeth M. Veenendaal,Hangqing Jin,Sophia Ran,Lawrence Cheung,Nora M. Navone,John W. Marks,Johannes Waltenberger,Philip E. Thorpe,Michael G. Rosenblum +8 more
TL;DR: These studies demonstrate the successful use of VEGF121/rGel fusion construct for the targeted destruction of tumor vasculature in vivo.
168
Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody
Jared M. Ashcroft,Dmitri A. Tsyboulski,Keith B. Hartman,Tatiana Y. Zakharian,John W. Marks,R. Bruce Weisman,Michael G. Rosenblum,Lon J. Wilson +7 more
TL;DR: The first fulleren (C60) immunoconjugates have been prepared and characterized as an initial step toward the development of fullerene immunotherapy (FIT).
124
Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells
Hong Zhou,John W. Marks,Walter N. Hittelman,Hideo Yagita,Lawrence H. Cheung,Michael G. Rosenblum,Jeffrey A. Winkles +6 more
TL;DR: The data support the use of an antibody–drug conjugate approach to selectively target and inhibit the growth of Fn14-expressing tumors.
84
Single-chain antibody based immunotoxins targeting Her2/neu. Design optimization and impact of affinity on antitumor efficacy and off-target toxicity
Yu Cao,James D. Marks,Qian Huang,Stephen I. Rudnick,Chiyi Xiong,Walter N. Hittelman,Xiaoxia Wen,John W. Marks,Lawrence H. Cheung,Kim Boland,Chun Li,Gregory P. Adams,Michael G. Rosenblum +12 more
TL;DR: Findings show that while high-affinity constructs can be potent antitumor agents, they may also be associated with mistargeting through the facile formation of complexes with soluble antigen leading to significant off-target toxicity.
70